Allogeneic hematopoietic cell transplantation (HCT) remains the only curative therapy for patients with relapsed/refractory, advanced and high-risk hematological malignancies. Although HLA-identical siblings are currently considered to be the preferred donor source for allogeneic HCT, only 25-30% of patients have such a donor. Alternative donor options include, unrelated donors (URD), umbilical cord blood units and haplotype-mismatched (haplo) related donors. The use of haplo-HCT is increasing based on recent promising results [1] [2] [3] [4] and the near-universal availability of this option. However, graft rejection is not uncommon (10-15%) after haplo-HCT and can be life threatening. 1 Although second allografts are an accepted strategy after rejection of an HLA-matched allograft, 5 there is paucity of data regarding second haplo-HCT in patients experiencing graft rejection after a prior haplo-HCT. In the current study, we report the toxicity and outcomes of salvage haplo-HCT using the post-transplant cyclophosphamide (PT-Cy) platform in five patients experiencing graft rejection after a prior haplo-HCT.
Adult patients with hematological malignancies who received a second salvage haplo-HCT for either primary or secondary graft rejection, following a prior haplo-HCT between January 2012 to January 2016 at our institution were eligible for this study. There were no other graft rejections following haplo-HCT during the era of the report, at our center. Primary graft rejection was defined as the failure to demonstrate donor-derived hematopoiesis after allogeneic HCT (that is, no evidence of donor-cell chimerisms of ⩾ 5% on unsorted or lineage-specific chimerism analysis (LSCA) at any time point post HCT), whereas complete loss of donor-cell chimerism (that is, o 5% donor-cells on chimerism analysis) after demonstrating evidence of donor-derived hematopoiesis was termed secondary graft rejection. Full donor chimerism was defined as the presence of ⩾ 95% of donor-cells on chimerism testing and mixed donor chimerism was defined as coexistence of recipient and donor hematopoietic cells (ranging from 5 to 94%), following allogeneic HCT. 5 Neutrophil recovery was defined as the first of 3 successive days with ANC ⩾ 500/μL after posttransplantation nadir. Platelet recovery was defined as achieving platelet counts ⩾ 20 000/μL for the first of 3 successive days, unsupported by transfusion. All recipients of haplo-HCT at our institution are screened for the presence of donor-specific antibodies (DSAs). The method used for detection of DSA in our study was solid-phase HLA antibody identification assays. 6 The mean fluorescent intensity (MFI) values provide a relative indication of the strength of the DSAs. The general cutoff value in our laboratory for a positive antibody is an MFI 41000.
Among all the patients receiving a first haplo-HCT during the study period (n = 40), three patients had primary graft rejection and two patients experienced secondary graft rejection ( Table 1) . The median time interval between diagnosis and first haplo-HCT was 7 months (range 3-9 months), with bone marrow (BM) as the graft source. The median age of the donors was 25 years (range 22-62 years); all were ABO matched with the recipients except for unique patient number-3 (UPN; patient/donor: A+/O+). All patients received reduced-intensity conditioning (RIC) with fludarabine (Flu; 25 mg/m 2 for 5 days starting on day − 6 to − 2), Cy (14.4 mg/m 2 for 2 days on day − 3 and − 2) and 200 cGy total body irradiation (TBI, on day − 1) followed by infusion of fresh BM grafts procured on day 0. None of the patients had detectable DSAs before the first HCT. GvHD prophylaxis consisted of PT-Cy, tacrolimus (0.015 mg/kg twice daily starting day +5 to target a level of 5-15 ng/ml) and mycophenolate mofetil (15 mg/kg starting day +5 through +35). Four patients received 50 mg/kg Cy on day +3 and one, UPN-5, received Cy 50 mg/kg on days +3 and +4 (Table 1 ). LSCA after transplantation showed no evidence of donor-derived hematopoiesis in the three patients with primary graft rejection. The two patients with secondary graft rejection initially showed signs of donor-derived hematopoiesis on day 30, but subsequently had o 5% donor-cells on days 60 and 180 for UPN-3 and UPN-5, respectively (Table 1) . Disease assessment at the time of graft rejection, ruled out relapsed disease in all patients. None of the patients at the time of graft rejection had evidence of human herpes virus-6, cytomegalovirus, Epstein-Barr virus or adenovirus reactivation.
All haplo-HCT recipients experiencing graft rejection in our center underwent a salvage second haplo-HCT. The median time interval between the first and second haplo-HCT was 42days (range 37-196days). For the salvage haplo-HCT, a different haploidentical-related donor was used in all cases. The median age of the donors for second haplo-HCT was 34years (range 25-39years) and all were ABO matched with their recipients except for UPN-1 (patient/donor: B+/O+). Two patients received myeloablative conditioning with Flu (25 mg/m2 for 5days starting day-6 to -2), intravenous busulfan (Bu) (110 mg/m 2 for 4 days starting day-7 to -4) and Cy (14.4 mg/m 2 for 2 days on day-3 and -2). Three patients had RIC with Flu (40 mg/m 2 for 4 days starting day-5 to -2), melphalan (Mel) (140 mg/m 2 on day-6) and 200 cGy TBI (on day-1). All patients received peripheral blood (PB) allografts. Four patients had no detectable DSAs prior to second haplo-HCT while one patient (UPN-3) had low level DSA detected (855 MFI). All patients received two doses of PT-Cy (on days +3 and +4), with rest of the GvHD prophylaxis regimen remaining the same as first haplo-HCT (Table 2 ).
All patients achieved neutrophil and platelet recovery, except UPN-3 ( Table 2 ). All patients except UPN-3 achieved full donor-cell chimerism, as summarized in Table 2 . Only one patient (UPN-4) experienced acute GvHD (skin stage 3, grade 2) on day +48. This patient also developed moderate chronic GvHD. No other patient had chronic GvHD. Three patients died after the second haplo-HCT. UPN-1 died from cerebral toxoplasmosis. UPN-2 and -3 died from veno-occlusive disease (VOD). The two surviving patients are alive and disease-free at days +412 and +585 following the salvage haplo-HCT.
Graft rejection is a potentially lethal complication of allogeneic transplantation. Experience with haplo-HCT as a salvage modality after graft rejection following a prior haplo allograft is limited. In our series we show that, whereas a small subset of patient can achieve long-term survival with stable donor-cell chimerisms after a second haplo-HCT, the procedure-related mortality is high.
Majority of published data for second allografts performed for graft failure are derived from the HLA-matched setting. The Center Letter to the Editor Table 2 . Unsorted chimerism analysis (CD33 of donor origin was 98%).
Letter to the Editor for International Blood and Marrow Transplant Research (CIBMTR) reported outcomes of second URD-HCT for primary graft failure (n = 122). Treatment-related mortality was high (86%), with a dismal 1-year survival of 11%. 5 The major factors for graft rejection after allo-HCT with standard calcineurin-based GvHD prophylaxis include degree of HLA-mismatch, alloimmunization to donor antigens, graft source and use of T-cell depletion. Mismatches at HLA-DRB1, HLA-C, HLA-A and HLA-B are associated with an increased risk of graft rejection, especially if the mismatch is in the graft rejection direction. 7, 8 DSAs are associated with a two to tenfold increase of graft failure after HLA-mismatched HCT. 9, 10 In a report by Ciurea et al. 11 (n = 24), 75% of recipients with detectable DSAs pre-transplantation experienced primary graft rejection. This study demonstrated the importance of pre-transplant DSA testing to prevent graft rejection. In our study, none of the patients had positive DSAs prior to initial or salvage haplo-HCT.
Recently, the CIBMTR investigated risk factors for primary graft failure after HLA-matched, myeloablative allo-HCT. In the study, there was a threefold higher risk of primary graft failure when BM was used as the graft source. Age o 30years, Karnofsky performance score of o 90% and advanced disease state were also associated with higher risk of primary graft failure. 12 Although our sample size is small, two out of five patients undergoing salvage haplo-HCT in our study developed VOD. Although one such patient received Bu-based myeloablative conditioning, that is associated with increased VOD risk, 13 the second patient underwent RIC HCT. The incidence of VOD is lower following RIC (5.7%) compared with myeloablative conditioning (11.9%).
14 There are several factors that may have led to rejection in our study. However, two risk factors that stand out include-BM graft (n = 5) and single dose of PT-Cy (n = 4). It is plausible that the wider application of PB as graft source for haplo-HCT can reduce the risk of graft rejection. However it is not clear if the low rates of chronic GvHD seen with PT-Cy-based BM haplo-HCT would be reproducible with PB haplo-HCT. All the patients in our study received non-myeloablative conditioning with Flu/Cy/TBI for first haplo-HCT, which may have also increased their risk. In order to reduce the risk of a second rejection, more intense conditioning regimens were used (Flu/Bu/Cy and Flu/Mel/TBI) for the second haplo-HCT. In addition, we used a different haploidentical-related donor, employed two doses of PT-Cy and used PB as a graft source. 11, 15 Of note; Luznik et al. 1 reported no difference in graft failure rates when comparing one versus two doses of PT-Cy. It also possible that the relatively low CD34 + cell doses administered, contributed to graft rejection in our series. In conclusion; we report that second haplo-HCT after experiencing graft rejection from a prior haplo-HCT can salvage a small subset of patients, but morbidity and mortality in this setting remains high.
